68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET

被引:35
作者
Zhang, Jun [1 ,2 ]
Lu, Xiaoli [1 ]
Wan, Nan [1 ]
Hua, Zichun [3 ]
Wang, Zizheng [1 ]
Huang, Hongbo [4 ]
Yang, Min [4 ]
Wang, Feng [1 ,3 ]
机构
[1] Nanjing Med Univ, Nanjing Hosp 1, Nanjing 210006, Jiangsu, Peoples R China
[2] Taizhou Peoples Hosp, Taizhou 225300, Jiangsu, Peoples R China
[3] Nanjing Univ, Dept Biochem, State Key Lab Pharmaceut Biotechnol, Nanjing 210000, Jiangsu, Peoples R China
[4] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Wuxi 210463, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
NGR peptide; APN; CD13; Tumor angiogenesis; Ga-68; labeling; DIMERIC NGR PEPTIDES; AMINOPEPTIDASE-N; CLINICAL-SIGNIFICANCE; DRUG-DELIVERY; CD13; RECEPTOR; ANGIOGENESIS; HTNF; VASCULATURE; COMBINATION; EXPRESSION;
D O I
10.1016/j.nucmedbio.2013.12.008
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aminopeptidase N (APN) is selectively expressed on many tumors and the endothelium of tumor neovasculature, and may serve as a promising target for cancer diagnosis and therapy. Asparagineglycine-arginine (NGR) peptides have been shown to bind specifically to the APN receptor and have served as vehicles for the delivery of various therapeutic drugs in previous studies. The purpose of this study was to synthesize and evaluate the efficacy of a Ga-68-labeled NGR peptide as a new molecular probe that binds to APN. Methods: NCR peptide was conjugated with 1,4,7,10-tetraazacyclododecane-N,N ',N '',N '''-tetraacetic acid (DOTA) and labeled with Ga-68 at 95 degrees C for 10 min. In vitro uptake and binding analysis was performed with A549 and MDA-MB231 cells. Biodistribution of Ga-68-DOTA-NGR was determined in normal mice by dissection method. Ga-68-DOTA-NGR PET was performed in A549 and MDA-MB231 xenografts, and included dynamic and static imaging. APN expression in tumors and new vasculatures was analyzed by immunohistochemistry. Results: The radiochemical purity of Ga-68-DOTA-NGR was 98.0%+/- 1.4% with a specific activity of about 17.49 MBq/nmol. The uptake of Ga-68-DOTA-NGR in A549 cells increased with longer incubation times, and could be blocked by cold DOTA-NGR, while no specific uptake was found in MDA-MB231 cells. In vivo biodistribution studies showed that Ga-68-DOTA-NGR was mainly excreted from the kidney, and rapidly cleared from blood and nonspecific organs. MicroPET imaging showed that high focal accumulation had occurred in the tumor site at 1 h post-injection (pi) in A549 tumor xenografts. A significant reduction of tumor uptake was observed following coinjection with a blocking dose of DOTA-NGR, whereas only mild uptake was found in MDA-MB231 tumor xenografts. Tumor uptake, measured as the tumor/lung ratio, increased with time peaking at 12.58 +/- 1.26 at 1.5 h pi. Immunohistochemical staining confirmed that APN was overexpressed on A549 cells and neovasculature. Conclusions: Ga-68-DOTA-NGR was easily synthesized and showed favorable biodistribution and kinetics. (68)GaDOTA-NGR could also specifically bind to the APN receptor in vitro and in vivo, and might be a potential molecular probe for the noninvasive detection of APN-positive tumors and neovasculature. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 38 条
[11]  
FUJII H, 1995, CLIN EXP METASTAS, V13, P337
[12]   Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis [J].
Fukasawa, Kazuteru ;
Fujii, Hideji ;
Saitoh, Yurika ;
Koizumi, Keiichi ;
Aozuka, Yasushi ;
Sekine, Keiko ;
Yamada, Masatoshi ;
Saiki, Ikuo ;
Nishikawa, Kiyohiro .
CANCER LETTERS, 2006, 243 (01) :135-143
[13]   Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours [J].
Gregorc, V. ;
Santoro, A. ;
Bennicelli, E. ;
Punt, C. J. A. ;
Citterio, G. ;
Timmer-Bonte, J. N. H. ;
Cappio, F. Caligaris ;
Lambiase, A. ;
Bordignon, C. ;
van Herpen, C. M. L. .
BRITISH JOURNAL OF CANCER, 2009, 101 (02) :219-224
[14]   Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors [J].
Gregorc, Vanesa ;
De Braud, Filippo G. ;
De Pas, Tommaso M. ;
Scalamogna, Roberto ;
Citterio, Giovanni ;
Milani, Alessandra ;
Boselli, Sabrina ;
Catania, Chiara ;
Donadoni, Giovanni ;
Rossoni, Gilda ;
Ghio, Domenico ;
Spitaleri, Gianluca ;
Ammannati, Cristina ;
Colombi, Scialini ;
Caligaris-Cappio, Federico ;
Lambiase, Antonio ;
Bordignon, Claudio .
CLINICAL CANCER RESEARCH, 2011, 17 (07) :1964-1972
[15]   Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer [J].
Hashida, H ;
Takabayashi, A ;
Kanai, M ;
Adachi, M ;
Kondo, K ;
Kohno, N ;
Yamaoka, Y ;
Miyake, M .
GASTROENTEROLOGY, 2002, 122 (02) :376-386
[16]  
Ishii K, 2001, INT J CANCER, V92, P49, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1161>3.0.CO
[17]  
2-S
[18]   Modification of Cyclic NGR Tumor Neovasculature-Homing Motif Sequence to Human Plasminogen Kringle 5 Improves Inhibition of Tumor Growth [J].
Jiang, Weiwei ;
Jin, Guanghui ;
Ma, Dingyuan ;
Wang, Feng ;
Fu, Tong ;
Chen, Xiao ;
Chen, Xiwen ;
Jia, Kunzhi ;
Marikar, Faiz M. M. T. ;
Hua, Zichun .
PLOS ONE, 2012, 7 (05)
[19]   Radiolabeled Cyclic RGD Peptides as Integrin αvβ3-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency [J].
Liu, Shuang .
BIOCONJUGATE CHEMISTRY, 2009, 20 (12) :2199-2213
[20]   HUMAN MYELOID PLASMA-MEMBRANE GLYCOPROTEIN CD13 (GP150) IS IDENTICAL TO AMINOPEPTIDASE-N [J].
LOOK, AT ;
ASHMUN, RA ;
SHAPIRO, LH ;
PEIPER, SC .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (04) :1299-1307